Amgen (AMGN -0.7%) initiates a Phase 3 cardiovascular outcomes (CV) study, GALACTIC-HF, assessing omecamtiv mecarbil in patients with high-risk chronic heart failure and reduced ejection fraction. The trial will determine if omecamtiv mecarbil, when added to standard-of-care (SOC) treatment, is superior to placebo plus SOC in reducing CV death or heart failure events.
The study will be conducted across 800 sites in 34 countries. Target enrollment is ~8,000.
The action triggers a $26.7M milestone payment to discoverer Cytokinetics (CYTK -4.2%).
Omecamtiv mecarbil is a cardiac myosin activator. Myosin is a protein in heart muscle that is responsible for converting chemical energy into the mechanical energy that results in a heart beat. Cardiac myosin activators increase systolic ejection time which results in an increase in cardiac contractility and more oxygen-efficient cardiac function.
The companies inked a strategic alliance to develop cardiac myosin activators in January 2007.